Parmax Pharma Ltd - 540359 - Approval Of The Unaudited Financial Results For Quarter Ended 30Th June, 2020.
Approval of the Unaudited Financial Results for quarter ended 30th June, 2020.15-09-2020
15-09-2020
Parmax Pharma Ltd - 540359 - Outcome Of The Proceedings Of The Meeting Of The Board Of Directors Of The Company
This is to inform you that the Board of Directors of the Company has, at its meeting held today, inter-alia, considered and approved the Unaudited Financial Results for quarter ended 30th June, 2020. A copy of the Statement of Unaudited Financial Results for the quarter ended 30th June, 2020, approved by the Board pursuant to Regulation 33 of the Securities And Exchange Board of India (LODR Regulations, 2015, is enclosed for your reference and record. The meeting was concluded on 6:45 pm. Further to inform you that the 26th Annual General Meeting of the Company will be held on Friday, 16th October, 2020 at the registered office of the Company.15-09-2020
Parmax Pharma Ltd - 540359 - Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Reg. 29 Read With Reg. 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/09/2020 ,inter alia, to consider and approve With reference to the captioned subject, we would like to inform you that the Meeting of the Board of Directors of Parmax Pharma Limited will be held on Tuesday, 15th September, 2020 at 02.00 PM inter alia to consider, approve the Unaudited Financial Results for the quarter ended 30th June, 2020 and to discuss any other matter with the permission of Board. You are requested to kindly take the above information on your record.09-09-2020
Parmax Pharma Ltd - 540359 - Intimation For Temporary Closure Of Company'S Manufacturing Unit.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that as per directives of conditional order issued by the Deputy Collector and Sub Divisional Magistrate Rajkot City -2, the Company has temporarily closed its production in the unit, till the subsequent order of the Competent Authority in this regard. Further, the company would be implementing additional COVID-19 related measures at the plant during this time. In addition, the company would also be implementing automation/semi-automation of manufacturing processes in certain areas of the said facility, and some annual maintenance to utilize this closure time prudently.25-08-2020
Parmax Pharma Ltd - 540359 - Audited Financial Results For Quarter And Financial Year Ended 31St March,2020
Further to our letter dated 24th July, 2020 and pursuant to the Regulation 33 and 30 of SEBI (Listing Obligations and Disclosure Requirement), Regulations 2015 we wish to inform you that the Board of Directors of the Company in its meeting held today, i.e. 31st July, 2020, have considered and approved the following: The Audited standalone financial results for the quarter and financial year ended 31st March, 2020. Appointment of CS Samsad Alam Khan, Practicing Company Secretaries, (Membership No. A28719) as a Secretarial Auditor of the Company for Financial Year 2020-21. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement), Regulations 2015, we enclose herewith: Audited Standalone Financial Results for the quarter and year ended 31st March, 2020. Independent Auditor's Report on the Audited Financial Results for the quarter and year ended 31st March, 2020. The Meeting of Board of Directors was commenced at 2.00 p.m. and concluded at 6.50 pm.31-07-2020
Parmax Pharma Ltd - 540359 - Audited Financial Results For Quarter And Year Ended 31St March, 2020
Audited Financial Results for Quarter and Year Ended 31st March, 202031-07-2020
Parmax Pharma Ltd - 540359 - Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Reg. 29 Read With Reg. 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2020 ,inter alia, to consider and approve Pursuant to Regulation 29(1) and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to notify that a meeting of the Board of Directors of the Company is proposed to be held on Friday, the 31st July, 2020 at 2:00 P.M. to, inter-alia, consider, approve and take on the record the Audited Financial Results for the year ended 31st March, 2020.24-07-2020
Parmax Pharma Ltd - 540359 - Shareholding for the Period Ended June 30, 2020
Parmax Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here21-07-2020
Parmax Pharma Ltd - 540359 - Subject: Update Regarding Production Of Intermediates Of ''Hydroxy Chloroquine''
Dear Sir /Madam, In continuation of our corporate announcement dated 25th April, 2020 in which we have informed about the production of intermediates of ''Hydroxy chloroquine'' (''Product'') on the basis of process and specifications provided by the Cadila Healthcare Ltd (CHL). In this regard we hereby informing that due to acute decline in demand of product the Company has temporarily stopped the production of ''Hydroxy chloroquine'' till further order and instructions of CHL. Further Company is in business of manufacturing of Pharmaceutical Drug Intermediates, Bulk Drugs and Specialty chemicals hence production / stop production of intermediates of ''Hydroxy chloroquine'' is general character, nature of our business and it is not material events as specified in Part B of Schedule III, read with Regulation 30(4) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Company is voluntarily making this disclosure by following good corporate governance practice.16-07-2020